In recent years, the use of positron emission tomography (PET) agents targeting prostate-specific membrane antigen (PSMA) has greatly improved the accuracy of prostate cancer (PCa) metastasis detection compared with conventional imaging [1, 2]. Here, FOLH1 is linked to prostate cancer.